Lin Yu
Managing Partner
Co-Founder
-
Education
University of San Diego: J.D.
University of California, San Diego: Ph.D. in Medicinal Chemistry
Zhongshan University: B.S. in Chemistry
Admissions
State of California
U.S. Patent and Trademark Office
Previous Experiences
Jones Day
Triad Pharmaceuticals, Inc.Brief Biography
Lin has more than 15 years of experiences enforcing and defending patents around the globe, driving patent portfolio strategy for drug candidates and FDA approved products, and conducting due diligence for life sciences companies and investment firms.
Lin's practice focuses on global patent portfolio development, patent life-cycle management, and patent enforcement in the areas of biotechnology and pharmaceuticals. Lin has devised global patent strategies for small molecule drugs, therapeutic antibodies, antibody drug conjugates, and nucleotide therapies. Lin has also advised established and emerging pharmaceutical and biotechnology companies on the strategic planning and acquisition of intellectual property portfolios. Lin's experiences include patent portfolio evaluations and due diligence investigations, including patentability, invalidity, infringement, and freedom-to-operate investigations.Lin developed and managed patent portfolios for many FDA approved products. Commercial products for which Lin has experience include Alunbrig®, Bravecto®, Kuvan®, Kyprolis®, Nerlynx®, Nuplazid®, Pomalyst®, Revlimid®, and Xospata®. Among them, Revlimid® is the top selling small molecule drug in 2020 with global sales about $12 billion.
Lin conducted numerous patent due diligences, including a few dozens for Baker Brothers Investments in support of its investment in biotech and pharmaceutical companies; the $74 billion merger of Celgene with BMS; the $5.2 billion acquisition of Ariad Pharmaceuticals by Takeda; and the $4.2 billion acquisition of the worldwide consumer health business of Merck KCaA by Procter & Gamble.
Lin was a member of the trial team that achieved the record-setting patent infringement verdict for Idenix (Merck & Co.), the largest infringement verdict in U.S. history in the amount of $2.54 billion against Gilead for its HCV drugs.
Before his legal career, Lin co-founded Triad Therapeutics, served as vice president of chemistry and biochemistry, and oversaw the development of its small molecule kinase inhibitors for rheumatoid arthritis, which was later licensed to Novartis.
-
Prosecution, Counseling, and Diligence Investigations
● Represent Celgene Corporation in its global patent prosecution, portfolio development, and patent life-cycle management relating to Revlimid® and Pomalyst®.● Represent BioMarin Pharmaceutical Inc. in its global patent prosecution, portfolio development, and patent life-cycle management relating to Kuvan®.
● Represent Puma Biotechnology, Inc. in its global patent prosecution, portfolio development, and patent life-cycle management relating to Nerlynx®.
● Represent Ambit Biosciences (acquired by Daiichi Sankyo) in its global patent prosecution, portfolio development, and patent life-cycle management relating to Xospata®.
● Represent Astellas Pharma Inc. in its global patent prosecution and portfolio development relating to its antibody-drug conjugate technologies.
● Represent Chevron Corporation in its global patent prosecution and portfolio development relating to its quasi-living polymer technologies; provide a freedom-to-operate opinion on its lubricant technologies.
● Represent BioTheryX, Inc. in its global patent prosecution, portfolio development, and patent life-cycle management relating to its molecular glue and PROTAC technologies.
● Represent Ascentage Pharma in its global patent prosecution, portfolio development, and patent life-cycle management relating to its Phase II clinical compound.
● Represent Hua Medicines (Shanghai) Ltd. in its global patent prosecution, portfolio development, and patent life-cycle management relating to its Phase III clinical compound.
● Represent Takeda Pharmaceuticals U.S.A., Inc. in the global filings of post-regulatory approval patent listings and patent term extension/supplemental protection certificate applications relating to Alunbrig®.
● Represent Acadia Pharmaceuticals, Inc. in conducting a pre-litigation analysis of its patent portfolio relating to Nuplazid® in anticipating Hatch-Waxman litigations.
● Represent Baker Brothers in about 2 dozen investment-related IP due diligence investigations relating to small molecule drugs, peptide and protein drugs, and virus-based immunotherapy.
● Represent Celgene Corporation in the intellectual property and technology transactions aspects of the $74 billion merger with Bristol-Myers Squibb.
● Represent Takeda Pharmaceuticals U.S.A., Inc. in the intellectual property aspect of the $5.2 billion acquisition of Ariad Pharmaceuticals.
Global Patent Litigation
● Represent Idenix (Merck & Co.) in enforcing Idenix’ U.S. Patent No. 7,608,597 against Gilead, obtaining the largest patent infringement verdict against Gilead for its hepatitis C drugs Sovaldi® and Harvoni®.● Represent Idenix (Merck & Co.) in defending an Idenix’ nucleoside analogue patent in Norway appeal against Gilead.
● Represent Idenix (Merck & Co.) in the Patents Court and Court of Appeal in patent litigation against Gilead in UK over its hepatitis C drugs Sovaldi® and Harvoni®.
● Represent Daikin Industries, Ltd. in defending against a patent infringement action brought by Chemours Company FC, LLC, relating its fluoropolymer products.
Global Post-Grant Proceedings
● Represent Idenix (Merck & Co.) in challenging Gilead’s patent rights relating to Sovaldi® in two patent interference proceedings at the US Patent Trial and Appeal Board.● Represent Idenix (Merck & Co.) in defending its nucleoside patent in opposition proceedings before the EPO related to Idenix’ patent covering nucleoside analogs and prodrugs.
● Represent Akebia Therapeutics, Inc. in successfully challenging the validity of European Patent No. EP 1463823 issued to FibroGen, Inc. in opposition proceedings before the EPO.
● Represent Takeda Pharmaceuticals U.S.A., Inc. in successfully requesting for supplemental examination relating to Kyprolis®.
● Represent Daikin Industries, Ltd. as the Petitioner for inter partes review of all claims of two patents owned by Chemours. The PTAB granted both IPR petitions with regard to all claims.
